-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Benzinga·10/01/2026 12:53:01
Diffusion vocale
Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.